Programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) antibodies have demonstrated impressive results in the treatment of patients with metastatic NSCLC without targetable mutations [1]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.